Quantum Advantage Forecast to Arrive Around 2039, UBS Reports

UBS forecasts quantum advantage, the point at which quantum computers outperform classical supercomputers, will arrive around 2039, a timeline slightly later than some estimates but indicating a rapidly approaching milestone. This anticipated leap in computational power builds on the momentum of artificial intelligence, with the AI-driven drug discovery market projected to reach 74.6 billion USD by an unspecified date, as companies invest in advanced capabilities. Quantum computers promise to amplify these gains, fostering a relationship between the two technologies and potentially revolutionizing biopharmaceutical innovation. As Alex Zhavoronkov, founder and CEO of Insilico Medicine, noted at the recent Asian Investment Conference, “Right now, quantum is in a very similar state as generative AI was in 2014, when we demonstrated that it is possible to use generative adversarial networks for small molecule design.” However, this emerging technology also presents significant cybersecurity risks, prompting experts to urge immediate preparation for a future where current encryption methods may be vulnerable.

Quantum Computing Potential in Biopharmaceutical Innovation

This anticipated capability is expected to significantly amplify gains already being made in artificial intelligence-driven drug discovery, a market projected to reach 74.6 billion USD by an unspecified date, as healthcare companies increasingly integrate AI or build in-house capabilities. Quantum computing is not a replacement for AI in biopharmaceuticals, but rather an enhancement, promising to tackle previously intractable problems in molecular simulation and design. UBS Japan Pharmaceuticals Analyst Atushi Seki highlights the potential for drastically reduced drug discovery timelines, suggesting identification of preclinical candidates could occur within 12, 18 months at a cost of only 3, 5 million USD, a substantial decrease from the traditional 4, 5 years and over 100 million USD. These efficiencies stem from quantum’s ability to accelerate complex calculations, but the technology’s implications extend beyond speed; it represents a fundamental shift in computational power capable of solving problems in seconds that would take classical computers millennia, creating both opportunities and risks for the biopharmaceutical sector and beyond.

Quantum Threat to Existing Encryption and Cybersecurity

The escalating development of quantum computing presents both opportunities and risks for cybersecurity, shifting the focus from theoretical vulnerability to imminent engineering challenges. While the timeline for achieving full quantum advantage remains debated, UBS forecasts this milestone will arrive around 2039, the threat to existing encryption standards is no longer distant. Experts emphasize that the risk is not simply whether quantum computers will break current encryption, but that data is already vulnerable to future decryption. “Data is vulnerable to being harvested and potentially decrypted later,” explained Andrew Grotto, Director of Stanford’s Geopolitics, Technology and Governance Program, speaking at the Asian Investment Conference. This proactive harvesting anticipates a future capability, allowing adversaries to unlock encrypted information once sufficiently powerful quantum computers become operational. Grotto clarified that a quantum computer capable of breaking commercial encryption is now considered an engineering problem, not a physics one, demanding immediate preparation. This urgency is driving innovation surrounding post-quantum cryptography, with organizations worldwide racing to develop new encryption methods resilient to quantum attacks. This ecosystem is dynamic, as companies position themselves to lead the transition to these security protocols. However, these defensive measures are not solely reactive; they represent a significant opportunity for growth. The challenges posed by quantum computing are fostering investment and development in cybersecurity, creating a competitive landscape for companies specializing in quantum-resistant solutions. Insilico Medicine founder and CEO, Alex Zhavoronkov, is actively charting a course for the integration of quantum computing into biopharmaceutical innovation, anticipating significant advancements within the next five years.